Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421304 · ClinicalTrials.gov registry record · NA
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
A NA study, sponsored by MedImmune.
- Completed
- Registry status
- NA
- Development phase
- 118
- Enrollment target
NCT00421304 is a NA study that has completed, run by MedImmune. The registered enrollment target is 118 participants.
The verdict
NCT00421304, a NA study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- NA
- Development phase
- 118 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the effect of a single dose of medication compared to placebo in the upper respiratory tract in previously healthy children less than or equal to 12 months of age who are hospitalized with lower respiratory tract illness.
Interventions
- OTHER Placebo
- BIOLOGICAL Motavizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2007-01-10 |
| Est. Completion | 2009-09-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421304
The ClinicalTrials.gov registry entry for NCT00421304 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00421304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421304 about?
NCT00421304 is a clinical study titled "A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness". The primary objective of this study is to describe the effect of a single dose of medication compared to placebo in the upper respiratory tract in previously healthy children less than or equal to 12 months of age who are hospitalized with lower respiratory tract illness.
What is the current status of trial NCT00421304?
This trial is currently completed. It is a NA study. The enrollment target is 118 participants. The study started on 2007-01-10. Estimated completion is 2009-09-17.
What interventions are being tested in trial NCT00421304?
The interventions under investigation include: Placebo (OTHER), Motavizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00421304?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.